Evidence suggests that CD103 plays an important role in protective immunity against cancers of epithelial origin in TILs in ovarian cancer and melanoma, and the number of CD8+ CD103+ cells increase in response to treatment with anti-PD-1 in mice and humans [100]. This evidence concerns the gene CD8A and cancer.